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Introduction: Because of its high rate of metastasis, inflammatory breast cancer (IBC) has a poor prognosis
compared with non-inflammatory types of breast cancer (non-IBC). In a recent study, Lehmann and colleagues
identified seven subtypes of triple-negative breast cancer (TNBC). We hypothesized that the distribution of TNBC
subtypes differs between TN-IBC and TN-non-IBC. We determined the subtypes and compared clinical outcomes by
subtype in TN-IBC and TN-non-IBC patients.
Methods: We determined TNBC subtypes in a TNBC cohort from the World IBC Consortium for which IBC status
was known (39 cases of TN-IBC; 49 cases of TN-non-IBC). We then determined the associations between TNBC
subtypes and IBC status and compared clinical outcomes between TNBC subtypes.
Results: We found the seven subtypes exist in both TN-IBC and TN-non-IBC. We found no association between
TNBC subtype and IBC status (P = 0.47). TNBC subtype did not predict recurrence-free survival. IBC status was not a
significant predictor of recurrence-free or overall survival in the TNBC cohort.
Conclusions: Our data show that, like TN-non-IBC, TN-IBC is a heterogeneous disease. Although clinical characteristics
differ significantly between IBC and non-IBC, no unique IBC-specific TNBC subtypes were identified by mRNA gene-
expression profiles of the tumor. Studies are needed to identify the subtle molecular or microenvironmental differences
that contribute to the differing clinical behaviors between TN-IBC and TN-non-IBC.Introduction
Inflammatory breast cancer (IBC), with its clinical and
biological characteristics of rapid proliferation, is the
most aggressive form of breast cancer [1]. The preva-
lence of IBC in the United States ranges from 1% to 5%
of breast cancer cases [2,3]; however, IBC has a high re-
currence/metastasis rate compared with that of non-IBC
and commonly leads to breast cancer death. Because
current treatments do not result in long-term eradica-
tion of disease, there is an urgent need to define the* Correspondence: nueno@mdanderson.org
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reproduction in any medium, provided the orbiology of IBC to develop molecularly targeted therapies
that may prove more effective.
IBC is diagnosed on the basis of its well-recognized
clinical characteristics [4]. Because IBC occurs rarely, its
biologic behavior has not been elucidated clearly, and we
do not have a clear molecular signature of this disease.
Recently, both in vivo and in vitro experiments identified
genes that contribute to the aggressive phenotype of IBC
[5-15]. Bieche et al. [5] reported that cell-proliferation
genes are more strongly associated with IBC than with
non-IBC and that tumoral processes, including signaling
pathways associated with inflammation, cell transform-
ation, invasive growth, and angiogenesis, are altered more
in IBC than in non-IBC. Nguyen et al. [8], by using expres-
sion analysis of human cDNA, discovered that, comparedl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Ki-67 and genes associated with metabolic pathways and
lipid signaling. Their findings confirmed that the IBC
phenotype is hyperproliferative. Other studies have also in-
vestigated the specific biology of IBC. An in vitro study re-
vealed that epithelial-mesenchymal transition (EMT) is
associated with the migration and invasion of cells from
IBC cell lines [16], and much focus has been placed on de-
termining the role of EMT in tumor progression and me-
tastasis in IBC [17]. Zhang et al. [16] reported that the
epidermal growth factor receptor (EGFR) pathway was in-
volved in tumor growth and metastasis of IBC through
EMT and that EGFR expression was an independent and
poor prognostic factor in IBC [18,19].
About 20% to 40% of IBC cases are triple-negative
breast cancer (TNBC) [20-22], which has a worse prog-
nosis than breast cancers that are positive for ER, PgR,
and/or HER2. In contrast, only 15% to 20% of non-IBC
cases are TNBC. Many investigators have speculated that
the high percentage of TNBC is one of the reasons that
IBC has been associated with a more-aggressive clinical
course and decreased overall and breast cancer-specific
survival [23]. Recently, Lehmann et al. [24] reported that
TNBC can be classified into seven subtypes on the basis
of differential GE and gene ontologies: basal-like 1
(BL1), basal-like 2 (BL2), immunomodulatory (IM), mes-
enchymal (M), mesenchymal stem-like (MSL), luminal
androgen receptor (LAR), and unstable (UNS). We have
validated these subtypes in 146 TNBC patients with
gene-expression microarrays obtained from June 2000 to
March 2010 at our institution [25].
In the current study, we evaluated these seven TNBC
subtypes with respect to IBC. Because IBC behavior is
more aggressive and is clinically different from that of
non-IBC, we hypothesized that the distribution of TNBC
subtypes differs between TN-IBC and TN-non-IBC. We
initially speculated that the predominant TNBC subtypes
in TN-IBC would be BL1 and MSL, based on the biologic
characteristics shown by the gene-set enrichment analysis
in the Lehmann et al. article. BL1 is associated with the
enrichment of proliferation genes and increased Ki-67 ex-
pression, and MSL is associated with EMT and is consist-
ent with a claudin-low subtype of breast cancer. We tested
our hypothesis by applying the subtypes of Lehmann et al.
subtypes to a World IBC Consortium dataset that included
39 patients with TN-IBC and 49 patients with TN-non-
IBC. We also compared clinical outcomes in TN-IBC and
TN-non-IBC patients by subtype to investigate whether
these subtypes relate to the poor prognosis of TN-IBC.
Materials and methods
Patient cohorts and GE data
Three institutions contributed to the World IBC Con-
sortium dataset: The University of Texas MD AndersonCancer Center, Houston, TX (patients diagnosed with IBC
in 2000 through 2005); General Hospital Sint-Augustinus,
Antwerp, Wilrijk, Belgium (1996 through 2009); and
Institut Paoli-Calmettes, Marseille, France (1998 through
2008). The dataset also includes 252 non-IBC patients. We
obtained clinical data and GE profiles, as well as breast
cancer samples, for 389 patients from these three institu-
tions. All patients gave written informed consent for vol-
untary participation, and this study was approved by the
institutional review boards of all three participating cen-
ters. Samples were stored according to each institution’s
criteria, as described in the supplemental information
(see Additional file 1). IBC was defined according to
the consensus diagnostic criteria published by Dawood
et al. [22]. In total, 137 IBC patients (including 39 TN-
IBC patients) and 252 non-IBC patients (including 49
TN-non-IBC patients) were in the World IBC Con-
sortium database.
All patients were treated with use of a multidisciplin-
ary approach according to the guidelines of each center.
Most patients were treated with neoadjuvant chemother-
apy, with the addition of hormone therapy in patients
with ER expression, and with the addition of trastuzu-
mab in patients with HER2 amplification. In TNBC
patients, 21 (78%) of 27 IBC patients and 29 (66%) of
44 non-IBC patients received neoadjuvant chemother-
apy. Neoadjuvant regimens based on anthracycline and
taxanes, such as T-FAC (weekly paclitaxel followed by 5-
fluorouracil [5FU] + doxorubicin + cyclophosphamide), were
given at the treating physician’s discretion.
We identified TNBC status with use of GE profiling.
Originally, GE data were normalized with the MAS 5 al-
gorithm, mean centered to 600, and log 2 transformed.
Because 15 cases had no information on breast cancer-
receptor status by immunohistochemistry (IHC) and be-
cause we prefer effective utilization for the dataset, we
identified ER, PgR, and HER2 receptor status by using, re-
spectively, ESR1 (probe set 205225_at), PgR (208305_at),
and ERBB2 (216836_s_at) mRNA GE data. We con-
structed receiver operating characteristic curves to meas-
ure the predictive accuracy of the logistic regression
models, including ESR1, PgR, and ERBB2 mRNA GE levels.
Cases with normalized ESR1 mRNA expression >10.18
were considered ER-positive cases, those with PgR mRNA
expression >2.907 were considered PR positive, and
cases with ERBB2 mRNA expression >12.54 were con-
sidered HER2 amplified [26]. We identified 39 TN-IBC
patients. This statistical analysis was performed with
BRB-ArrayTools version 3.9.0 α software [27] and R
software version 2.7.2 [28].
The World IBC Consortium arrays were not initially
quantified as in Lehmann et al.; they used the RMA al-
gorithm, and our group used MAS 5.0. For consistent
quantification of the arrays, we used the fRMA algorithm,
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batches and then the data to be combined for analysis, to
normalize and quantify all the datasets before we applied
the Lehmann et al. approach. Clinicopathologic char-
acteristics of the TNBC patient cohorts are presented in
Table 1.
Identification of TNBC subtypes
In our previous study [25], we reproduced the algorithm
of Lehmann et al. and extracted the centroids of the seven
TNBC subtypes based on the training data (supplemen-
tary data). By using that same method, we assigned the 88
TNBC (TN-IBC, n = 39; TN-non-IBC, n = 49) samples in
the World IBC Consortium dataset to a TNBC subtype
with the use of both our approximated and Lehmann’s
gene signatures. We used the highest Pearson correlation
and lowest P value as the criteria to determine to which
subtype a specific sample belonged. We constructed two
7 × 2 contingency tables based on the gene signatures we
obtained and the original ones in Lehmann et al. The
Fisher Exact test was applied to compare the TN-IBC and
TN-non-IBC subtypes.
To determine the power of detecting an extreme shift,
we set the margins of the 7 × 2 table of subtypes by IBC
status, assigned a 0 to the first cell, randomly allocated the
rest, and computed the Fisher test P value. We repeated
this process 500 times and then moved to the next cellTable 1 Characteristics of patients with TNBC (n = 88)











49 (26-78) 56 (28-77) 0.1681
Clinical stage
of diagnosis
I 9 (19) 8.904e-09
II 17 (35)
III 27 (69) III 18 (36)
IV 5 (13) IV 5 (10)
Unknown 7 (18) Unknown 0 (0)
Nuclear grade I 0 (0) I 3 (6) 0.2048
II 4 (10) II 10 (20)
III 33 (85) III 35 (72)
Unknown 2 (5) Unknown 1 (2)
Tumor embolism Positive 24 (62) Positive 3 (6) 3.604e-09
Negative 12 (30) Negative 20 (41)




Positive 21 (78) Positive 29 (66) 0.1684
Negative 5 (18) Negative 15 (34)
Unknown 1 (4) Unknown 0 (0)(performing 7,000 tests in all). Our overall power (the
chance of getting a Fisher test P value of <0.05 when one
subtype is extremely different) was 3,304/7,000 = 0.472.
Survival analysis
We excluded stage IV patients for our survival analysis.
Follow-up data were available for 27 TN-IBC and 43
TN-non-IBC patients. The median follow-up periods
from diagnosis were 3.39 years (range, 0.84 to 6.48 years)
for IBC patients (n = 27) and 3.76 years (range, 0.29 to
10.78 years) for non-IBC patients (n = 43). We per-
formed log-rank tests to compare clinical outcomes in
TN-IBC and TN-non-IBC patients by subtype: overall sur-
vival (OS), distant metastasis-free survival (DMFS), and
recurrence-free survival (RFS). A Bonferroni-adjusted
P value (0.05 divided by the number of comparisons
made) was used as the cutoff to determine the signifi-
cance of the log-rank test results regarding the com-
parisons of TNBC subgroups. Cox models were used
to assess the relevance of the subtype classifications
overall. We then performed all pairwise comparisons
between subgroups with use of log-rank tests with a
Bonferroni adjustment to correct for multiple testing.
GE analysis
We examined differences among TNBC subtypes and
between IBC (stage III, IV) and non-IBC (stage III, IV)
at the GE level by using feature-by-feature linear mix-
ture models followed by fitting a beta-uniform mixture
(BUM) model to control for multiple testing. Numbers
of significant genes were counted for some selected false
discovery rates (FDRs). The Affymetrix U133 annotation
package hgu133a.db was used to export gene symbols
for each of the 22,283 probes.
Information on microarray data
Data sets for this study have been deposited into the
GEO database [29] under accession number GSE45584.
Results
Comparison between TN-IBC and TN-non-IBC
We classified each of our IBC and non-IBC samples into
one of the seven clusters by using gene signatures and
the highest correlation between the sample and the cen-
troid of each cluster. We constructed two 7 × 2 contin-
gency tables based on the gene signatures we obtained
(Table 2) and the original ones in Lehmann et al.
(Table 3). Then we compared the distributions of TN-
IBC and TN-non-IBC. With the Fisher Exact test, we
found no statistical differences in TNBC-subtype distri-
bution for patients with IBC or patients with non-IBC
(P = 0.47 and P = 0.22, respectively). We could not detect
differences between IBC and non-IBC in mRNA expres-
sion level that would explain the clinical aggressiveness
Table 2 Distribution of IBC/non-IBC status by TNBC
subtype by using MDA gene signatures
IBC (%) Non-IBC (%) P value
Subtype 1 (M) 4 (10.2) 6 (12.2) 0.47
Subtype 2 (IM) 4 (10.2) 12 (24.4)
Subtype 3 (BL1) 8 (20.5) 7 (14.2)
Subtype 4 (BL2) 3 (7.6) 2 (4.0)
Subtype 5 (LAR) 5 (12.8) 5 (10.2)
Subtype 6 (UNS) 7 (17.9) 12 (24.4)
Subtype 7 (MSL) 8 (20.5) 5 (10.2)
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lecular subtypes by using the TNBC population for
which triple negativity was identified by both IHC test
and mRNA expression level (N = 63). We had the same
results; no differences in TNBC subtype distribution be-
tween IBC and non-IBC were found (see Additional file
2: Table S5A, S5B).
Lehmann et al. used gene profiles of patients with
various stages of disease. However, all IBC cases are
stage III or IV. Therefore, we also analyzed stage-
matched populations (IBC, n = 32; non-IBC, n = 23). The
results indicated no significant association between
TNBC subtypes and IBC status at tumor stage III or
above, no matter which set of gene signatures was ap-
plied (P = 0.47, P = 0.77, respectively; data not shown).Clinical relevance of TNBC subgroups
Because the subtypes and distributions of TN-IBC were
similar to those of TN-non-IBC, we evaluated the clinical
effect of the TN-IBC subgroups among stage III patients,
focusing on the prognostic effect for survival data. Log-
rank tests and Cox proportional hazards models revealed
no significant differences between TNBC subtypes with
respect to OS, RFS, and DMFS (Figure 1A through C).
We analyzed both our original seven groups and the seven
Lehmann et al. groups, and results were similar (data not
shown).Table 3 Distribution of IBC/non-IBC status by TNBC
subtype by using Lehmann’s gene signatures
IBC (%) Non-IBC (%) P value
M 5 (12.8) 9 (18.3) 0.22
IM 5 (12.8) 12 (24.4)
BL1 12 (30.7) 10 (20.4)
BL2 1 (2.5) 4 (8.1)
LAR 6 (15.3) 6 (12.2)
UNS 2 (5.1) 5 (10.2)
MSL 8 (20.5) 3 (6.1)Therapeutic relevance of TNBC subgroups
Subsequently, we analyzed GE focusing on predictive ef-
fect for therapy selection. Lehmann et al. classified
breast cancer cell lines according to their subtypes.
Xenograft tumors established from their TNBC subtypes
displayed differential sensitivity to cisplatin, bicaluta-
mide, and NVP-BEZ235. Lehmann et al. showed that
their subtypes had a predictive effect relevant to therapy
selection. The BL1 and BL2 cell lines, for example,
which were associated with the DNA damage response,
were highly sensitive to cisplatin; the LAR cell line, which
expresses high levels of AR mRNA, was highly sensitive
to an AR antagonist; and the MSL cell line, associated
with the PI3K pathway, was highly sensitive to NVP-
BEZ235 (a PI3K/mTOR inhibitor).
On the basis of these results, we analyzed AR mRNA
expression levels in our subtypes. Only the efficacy of an
AR antagonist relative to the expression of AR has been
verified; we could not evaluate the efficacy of other
drugs through GE levels because cisplatin is not a tar-
geted drug, and the efficacy of NVP-BEZ235 depends
not on expression level but on mutations. In our dataset,
AR expression was significantly different between TNBC
subtypes. The boxplots of GE profiles of AR based on the
World IBC Consortium dataset are shown in Figure 2.
We selected the probes with the lowest P values from lin-
ear mixture models to represent these genes. As shown in
Figure 2, the AR expression level appears to be higher in
subtype 5 defined by our approximated gene signatures
and in subtype LAR defined by the gene signatures
of Lehmann et al. Our approximated TNBC subtype
5 had a high correlation with the LAR subtype. Also,
these results revealed the possibility that an AR antag-
onist could be an effective drug not only for LAR-TN-
non-IBC patients but also for LAR-TN-IBC patients.
Therefore, both the Lehmann et al. study and our study
showed that AR antagonists are a reasonable therapy in
TNBC and that their efficacy should be tested in pro-
spective studies.
Comparison of all gene structures in TN-IBC and
TN-non-IBC
To summarize our findings, we did not see a specific
biologic profile of TN-IBC. We therefore tested all
breast cancer samples (both TNBC and non-TNBC) to
compare IBC and non-IBC structures. The results from
two-sample t tests and the BUM model revealed that at
the molecular level, obvious differences existed between
IBC and non-IBC for all subtype patients at stage III or
above (Figure 3A). At an FDR of 1%, there were 317 sig-
nificant genes, which means that only three of these
genes would be expected to be selected by random
chance (false positive). When we restricted our attention
to TNBC while still focusing on stage III or above
Figure 1 Kaplan-Meier estimates. (A) Kaplan-Meier estimates for TNBC subtypes (defined by MDA approximated gene signatures) with respect to
overall survival (OS) of patients with stage III disease; (B) Kaplan-Meier estimates for TNBC subtypes (defined by MDA approximated gene signatures)
with respect to recurrence-free survival (RFS) of patients with stage III disease; (C) Kaplan-Meier estimates for TNBC subtypes (defined by MDA approxi-
mated gene signatures) with respect to distance metastasis-free survival (DMFS) of patients with stage III disease. The P values of the log-rank tests are
for each pair of TNBC subtypes with respect to OS. The subtypes were classified by using our approximated gene signatures. The Bonferroni-adjusted
P value is 0.00238. The P values of the log-rank tests are for each pair of TNBC subtypes with respect to RFS. The subtypes were classified by using our
approximated gene signatures. The Bonferroni-adjusted P value is 0.00238. The P values of the log-rank tests are for each pair of TNBC subtypes with
respect to DMFS. The subtypes were classified by using our approximated gene signatures. The Bonferroni-adjusted P value is 0.00238.
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FDR of 40%, suggesting no significant difference between
IBC and non-IBC restricted to high-tumor-stage TNBC.
Discussion
Our findings suggest that TN-IBC is a heterogeneous
disease. We found seven subtypes, including one un-
stable subtype, in TN-IBC, and these subtypes showed
high correlation with the seven Lehmann et al. subtypes.
In comparing TN-IBC and TN-non-IBC, the distribution
of these seven subtypes showed no statistical differences;
the TN-IBC samples were assigned to the seven groups
without any predominance, disproving our hypothesis.
In addition, we compared all TNBC mRNA gene signa-
tures for IBC and non-IBC and could find no specific
molecular signature in the IBC group. Thus, mRNAarray analysis showed that IBC and non-IBC have simi-
lar biology in TNBC.
Molecular techniques such as DNA microarrays provide
novel tools with which to investigate the heterogeneity of
breast cancer. To classify subgroups, it is necessary to
identify the most appropriate molecular-based therapies.
In breast cancer, five molecular subtypes have been re-
peatedly described in non-IBC [30-32], and these subtypes
have been strongly associated with clinical outcome and
drug sensitivity. Bertucci et al. [9] reported that the
expression signatures defining molecular subtypes of non-
IBC were also present in IBC, with similar expression
patterns. Focusing on the differences between IBC and
non-IBC, they suggested that the intrinsic biology associ-
ated with cell type was more important to determining
the transcriptional pattern than was the clinical aspect of
Figure 2 Boxplots of AR gene expression levels in TNBC subtypes defined by MDA-approximated gene signatures (left panel) or
Lehmann’s gene signatures (right panel).
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type and inflammatory character are two independent fea-
tures of breast cancers. Our results are consistent with
their interpretation and suggest that to identify the spe-
cific biology of IBC, we have to consider not only tumor
cells but also their microenvironment and other factors,Figure 3 IBC versus non-IBC at stage III or above. (A) Those without re
from two-sample t tests for IBC versus non-IBC. The overlaid curves are the
cutoffs are shown in a comparison of IBC with non-IBC.such as the effects of inflammation, immune pathways,
and mutations.
In addition, gene-structure analysis suggested that the
specific biology of IBC might be hidden in other breast
cancer groups, such as ER-positive and HER2-positive
groups. Van Laere et al. [33] and Woodward et al. [34]striction to TNBC and (B) those within TNBC. Histograms of P values
fitted BUM models. Counts of significant features with various FDR
Masuda et al. Breast Cancer Research 2013, 15:R112 Page 7 of 9
http://breast-cancer-research.com/content/15/6/R112also investigated the specific biology of IBC by using the
World IBC Consortium dataset but with a different ap-
proach. They identified potential genes specific to IBC
and found that the differences also were related not to
TNBC subtype but to ER-positive subtypes. However, al-
though many studies have examined and compared gene
expression between IBC and non-IBC, repeatedly finding
clusters associated with receptor subtype, no consistent
gene signature associated with IBC has been validated.
It is possible that our dataset was too small to reveal
fully differences in distribution, although our 39-case
TN-IBC population is the largest so far to be published.
As was found previously in the Nguyen et al. study [8],
we could not investigate the association of each pathway;
even if we could classify the TN-IBC subtypes according
to those described by Lehmann et al., the canonic path-
ways of each subtype partially overlap those of other
subtypes. Moreover, each pathway has correlations with
other pathways. Thus, in our study, we could not inves-
tigate the associations of several diverse pathways in IBC
and therefore could not indicate the differences in
TNBC-subtype distribution.
Lehmann et al. reported that their subtypes were asso-
ciated with significant differences in RFS (P = 0.0083).
Patient RFS was significantly decreased in the LAR sub-
type compared with the BL1, IM, and MSL subtypes.
However, patient characteristics varied, and their therap-
ies and durations of treatment were not standardized.
DMFS did not vary significantly between TNBC sub-
types. In our cases, in addition to the small numbers,
the median follow-up period for IBC patients (n = 27)
was 3.39 years (range, 0.84 to 6.48 years). We need a
longer follow-up time before we can discuss whether
these seven subgroups have a prognostic effect. As a re-
sult, neither we nor Lehmann et al. could verify the ef-
fect of TNBC subgroups as prognostic markers.
Lehmann et al. showed that their seven TNBC subtypes
displayed unique GE and ontologies. They also identified
representative subtypes of TNBC cell-line models and
predicted that “driver” signaling pathways were pharmaco-
logically targeted in these cell-line models as proof of
concept that the analysis of distinct GE signatures can im-
prove therapy selection. In our dataset, we determined
that the subgroups that showed the highest AR expression
level belonged to TN-IBC (subtype 5 and LAR subtype),
revealing the possibility that an AR antagonist can be a
potentially useful drug for these patients.
Conclusions
In this study, we addressed the question of whether the
aggressive behavior of IBC is tied to TNBC subtype. The
results suggested that TN-IBC is a heterogeneous dis-
ease. Our findings showed that TNBC subtype classifica-
tion is not affected by IBC or non-IBC status. TN-IBCand TN-non-IBC had the same subtypes by using
mRNA expression profiles. These findings lead to the
conclusion that the differences in TN-IBC and TN-non-
IBC are from a very subtle molecular difference or have
nothing to do with the tumor itself. It is also possible
that clinical diagnosis of TN-IBC in particular is not
reflected at the molecular level. These results point to a
need for elucidating the specific biology of TN-IBC by
focusing not only on its direct comparison with non-IBC
at the mRNA-expression level but also on its pathway
associations; they also show the need for whole-genome
deep DNA sequencing (International Cancer Genome
Consortium) and for further investigation of microenvi-
ronmental differences.
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